Quanterix announced “Simoa Accelerator” – a dedicated laboratory environment for clinical sample testing and development allowing broader access to an advanced diagnostic technology that has been fueling research in oncology, neurology, cardiology, infectious disease, etc.
Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the opening of The Simoa Accelerator, a dedicated laboratory environment for custom assay development and clinical sample testing. Designed to provide access to the revolutionary Single Molecule Array (Simoa) HD-1 Analyzer, this state-of-the-art facility allows users to experience the advantages of the technology firsthand.
With Simoa, life science researchers can explore biomarkers and pathways with greater sensitivity and precision, paving the way for the development of new diagnostic tests and improved treatment of diseases in oncology, neurology, cardiology and other fields of medicine. The Simoa Accelerator provides accessibility to this innovative technology, allowing customers to:
“The Simoa Accelerator provides immediate access to innovative, disruptive technology that is attracting a great amount of attention from academics, clinical researchers and scientists. During the initial pilot phase of this lab, Quanterix has already been able to undertake a significant number of projects with the majority of the leading global pharmaceutical companies and has achieved outstanding results. This unprecedented demand for Simoa is what led us to create and launch the Simoa Accelerator,” said Kevin Hrusovsky, Executive Chairman, Quanterix. “With new accessibility to the platform, we hope to accelerate the understanding and exposure of single molecule array technology so that end users can fully understand how Quanterix can help them to unlock a world of insight into disease detection, diagnosis and patient treatment.”
The Simoa Accelerator is now available at the Quanterix office in Lexington, Massachusetts. For more information, please visit: http://www.quanterix.com/literature/product-brochures/simoa-accelerator.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.